{
    "clinical_study": {
        "@rank": "146227", 
        "arm_group": {
            "arm_group_label": "PCI-32765 (Ibrutinib)", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to collect long-term safety and efficacy data for participants\n      treated with PCI-32765 (Ibrutinib) and to provide ongoing access to PCI-32765 for\n      participants who are currently enrolled in PCI-32765 studies that have been completed\n      according to the parent protocol, are actively receiving treatment with PCI-32765, and who\n      continue to benefit from PCI-32765 treatment."
        }, 
        "brief_title": "A Long-term Extension Study of PCI-32765 (Ibrutinib)", 
        "completion_date": {
            "#text": "December 2019", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Chronic Lymphocytic Leukemia", 
            "Small Lymphocytic Lymphoma", 
            "Mantle Cell Lymphoma", 
            "Follicular Lymphoma", 
            "Diffuse Large B-cell Lymphoma"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Leukemia", 
                "Leukemia, Lymphocytic, Chronic, B-Cell", 
                "Leukemia, Lymphoid", 
                "Lymphoma", 
                "Lymphoma, Follicular", 
                "Lymphoma, B-Cell", 
                "Lymphoma, Large B-Cell, Diffuse", 
                "Lymphoma, Mantle-Cell"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is an open-label (identity of assigned study drug will be known) study designed to\n      collect long-term safety and efficacy data and provide PCI-32765 (Ibrutinib) access to\n      participants in completed PCI-32765 studies. Participants will continue with the current\n      PCI-32765 dosing regimen established in the parent PCI-32765 study until the investigator\n      determines that the participant is no longer benefitting from treatment (ie, disease\n      progression or unacceptable toxicity has occurred), the study is terminated by the sponsor,\n      the participant withdraws consent, alternative access to PCI-32765 is available and\n      feasible, or for other reasons as defined in the protocol. Safety will be monitored\n      throughout the study and summarized. Efficacy may be analyzed in combination with the data\n      collected in the parent protocol. There is no formal hypothesis testing planned for this\n      long-term extension study. Participants can receive a maximum of 3 years of treatment with\n      single-agent PCI-32765 in this study."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Participants must be currently in a PCI-32765 clinical study considered completed and\n             have received at least 6 months of treatment with PCI-32765\n\n          -  At study entry, participants must be actively receiving treatment with single-agent\n             PCI-32765\n\n          -  Agrees to protocol-defined use of effective contraception\n\n          -  Negative blood or urine pregnancy test at screening\n\n        Exclusion Criteria:\n\n          -  Requires anticoagulation with warfarin or equivalent vitamin K antagonists\n\n          -  Requires treatment with strong cytochrome P450 (CYP)3A4/5 inhibitors, unless\n             previously approved by sponsor\n\n          -  Any condition or situation which, in the opinion of the investigator, may put the\n             participant at significant risk, may confound the study results, or may interfere\n             significantly with volunteer's participation in the study"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "200", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 4, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01804686", 
            "org_study_id": "CR100955", 
            "secondary_id": [
                "2012-004225-24", 
                "PCI-32765CAN3001"
            ]
        }, 
        "intervention": {
            "arm_group_label": "PCI-32765 (Ibrutinib)", 
            "description": "PCI-32765 (Ibrutinib) will be given orally as capsules, once daily continuously, according to the current dosing regimen established in the parent PCI-32765 clinical study (560 mg, 420 mg, 280 mg, or 140 mg), at least 30 minutes before eating or at least 2 hours after a meal, at approximately the same time each day.", 
            "intervention_name": "PCI-32765 (Ibrutinib)", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "Chronic lymphocytic leukemia", 
            "Small lymphocytic lymphoma", 
            "Mantle cell lymphoma", 
            "Follicular lymphoma", 
            "Diffuse large B-cell lymphoma", 
            "PCI-32765", 
            "Ibrutinib", 
            "Bruton's tyrosine kinase inhibitor"
        ], 
        "lastchanged_date": "May 19, 2014", 
        "link": {
            "description": "To learn how to participate in this trial please click here.", 
            "url": "http://pam.sylogent.com/cr/CR100955"
        }, 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Los Angeles", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Stanford", 
                        "country": "United States", 
                        "state": "California"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hackensack", 
                        "country": "United States", 
                        "state": "New Jersey"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Hyde Park", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Columbus", 
                        "country": "United States", 
                        "state": "Ohio"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Houston", 
                        "country": "United States", 
                        "state": "Texas"
                    }
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Charlottesville", 
                        "country": "United States", 
                        "state": "Virginia"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Bydgoszcz", 
                        "country": "Poland"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "London", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Withdrawn"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Manchester", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Plymouth", 
                        "country": "United Kingdom"
                    }
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "Poland", 
                "United Kingdom"
            ]
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase 3b, Multicenter, Open-label, PCI-32765 (Ibrutinib) Long-term Extension Study", 
        "overall_contact": {
            "email": "JNJ.CT@sylogent.com", 
            "last_name": "Use link at the bottom of the page to see if you qualify for an enrolling site (see list). If you still have questions:"
        }, 
        "overall_official": {
            "affiliation": "Janssen Research & Development, LLC", 
            "last_name": "Janssen Research & Development, LLC Clinical Trial", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "United States: Federal Government", 
                "Malaysia: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Number of participants affected by an adverse event", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 30 days after the last dose of study medication"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01804686"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Number of participants with change in disease status", 
            "safety_issue": "No", 
            "time_frame": "Up to the end-of-treatment visit (up to 30 days after the last dose of study medication)"
        }, 
        "source": "Janssen Research & Development, LLC", 
        "sponsors": {
            "collaborator": {
                "agency": "Pharmacyclics", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Janssen Research & Development, LLC", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}